DoW Amyotrophic Lateral Sclerosis Research Program, Therapeutic Development Award
Closed Posted
- Opportunity number
- HT942526ALSRPTDA
- Agency
-
Medical Command
Department of the Army, Department of Defense
- Applications due
- Award size
- Not on record
Opportunity facts
- Assistance listings
- Funding instrument
- Grant
- Category
-
- Science and Technology and other Research and Development
- Eligible applicants
-
- Unrestricted
- Points of contact
-
- eBRAP Help Desk help@ebrap.org (301) 682-5507
Opportunity details come from Grants.gov. Updated .
About this opportunity
The Defense Health Agency (through the Department of the Army Medical Command) is soliciting applications for the Fiscal Year 2026 Amyotrophic Lateral Sclerosis Research Program Therapeutic Development Award, with a full application due date of September 30, 2026, and a pre-application due date of June 24, 2026 at 5:00 p.m. ET.
Eligible applicants are unrestricted—extramural and intramural U.S. Department of War organizations, including foreign and domestic for-profit and nonprofit entities. Principal Investigators must be independent scientists at or above the independent scientist level and may lead no more than three FY26 ALSRP applications across all award mechanisms.
The Defense Health Agency expects to allot approximately $12.0 million to fund approximately six awards with a total cost cap of $2.0 million per award and a maximum performance period of three years. No cost share is specified.
Research must begin with lead compounds already in hand demonstrating proof-of-concept efficacy in at least one appropriate preclinical ALS model system. A critical requirement is parallel development of mechanism-specific, predictive/cohort-selective, target engagement, and pharmacodynamic biomarkers; biomarker development for diagnosis, prognosis, or general disease progression measurement without therapeutic consideration will not be supported. Clinical trials are prohibited, though validation studies using preexisting de-identified human specimens from well-characterized patient cohorts are encouraged. Applicants with limited ALS experience are strongly encouraged to include collaborators with substantial expertise in relevant ALS model systems, endpoints, and pathophysiology. Therapeutic candidates that have already been granted an IND are ineligible.
The application follows a two-step process: pre-application screening followed by invitation to submit a full application. Pre-applications are due June 24, 2026; selected applicants receive invitation to submit full applications on August 3, 2026. Full applications undergo peer review (November 2026) and programmatic review (January 2027), with awards anticipated by September 30, 2027 using FY26 funds expiring September 30, 2032.
The opportunity falls under CFDA 12.420 (Military Medical Research and Development).
Synopsis
Summary: The fiscal year 2026 (FY26) Amyotrophic Lateral Sclerosis Research Program (ALSRP) Therapeutic Development Award (TDA) supports research ranging from preclinical validation of therapeutic leads through U.S. Food and Drug Administration (FDA) Investigational New Drug (IND)-enabling studies. The proposed studies are expected to be empirical in nature and product-driven. Applicants with limited amyotrophic lateral sclerosis (ALS) experience are strongly encouraged to include collaborators with substantial experience in the relevant ALS model systems, endpoints and pathophysiology.
Applications supported by this award must begin with lead compounds in hand and must already demonstrate proof-of-concept efficacy data in at least one appropriate preclinical model system of ALS, including whole-animal and cellular model systems.
Distinctive Features: Mechanism-specific, predictive/cohort-selective, target engagement and pharmacodynamic biomarker development, in parallel to the main therapeutic effort, is a critical component of the FY26 ALSRP Therapeutic Development Award. If appropriate mechanism-specific biomarkers are already available or currently in development, how the existing biomarkers will improve trial design, patient selection, and efficiency or interpretation of the proposed ALS therapeutic approach must be apparent in the application. Development of biomarkers for the purposes of diagnosis, prognosis, or measurement of general disease progression without consideration of the therapeutic development process will not be supported.
Therapeutic candidates which have already been granted an IND are not appropriate for this mechanism.
Files
| File | Type | Posted |
|---|---|---|
| PKG00292625.pdf | ||
| HT942526ALSRPTDA_GG.pdf | ||
| HT942526ALSRPTDA_GG.pdf |
On GovTribe
Work this opportunity
- Track it in your pipeline
- Find teaming partners
- Similar grant opportunities
- Ask GovTribe AI about this opportunity